Clinical Trial Update: Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A phase 2 clinical trial in metastatic breast cancer is comparing Letrozole + Ribociclib vs Fulvestrant + Letrozole + Ribociclib in HR-positive, HER2-negative d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• Faslodex (fulvestrant)
• KISQALI (ribociclib)

Snippet

Sponsor: Korea University Guro Hospital | Conditions: Metastatic Breast Cancer | Phase 2 | Status: RECRUITING